Zuclopenthixol Long-acting IM Injection (Depot) bulk supplier for pharma manufacturers

Zuclopenthixol Long-Acting IM Injection (Depot) 200 mg/mL, 500 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Long-acting IM Injection (Depot)

Available Strengths: 200 mg/mL, 500 mg/mL

Reference Brands: Clopixol Depot (EU)

Zuclopenthixol is a typical antipsychotic that works by blocking dopamine (D2) receptors in the brain, reducing psychotic symptoms. It’s primarily used as a long-acting intramuscular injection to manage schizophrenia, particularly in patients with poor medication compliance. It helps maintain symptom control over extended periods.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Zuclopenthixol Long-Acting IM Injection (Depot)? List it or send an offer →

Product Description: Zuclopenthixol long-acting IM injection, a typical antipsychotic depot formulation, is not FDA-approved in the United States but is widely authorized in the EU under the brand Clopixol Depot. In Europe, it follows EMA guidelines for long-acting injectable neuroleptics, indicated for schizophrenia and related psychoses. EU compliance requires GMP manufacturing, stability data, and pharmacovigilance alignment. U.S. market entry may involve a 505(b)(2) pathway and complete ANDA dossier.

Zuclopenthixol Long-Acting IM Injection (Depot) — third party manufacturing & bulk supply

Zuclopenthixol Long-Acting IM Injection (Depot) 200 mg/mL, 500 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Zuclopenthixol Long-Acting IM Injection (Depot) is supplied as Long-acting IM Injection (Depot) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Zuclopenthixol Long-Acting IM Injection (Depot) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Zuclopenthixol Long-Acting IM Injection... →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Zuclopenthixol Long-acting IM Injection (Depot) is listed as Long-acting IM Injection (Depot) in 200 mg/mL, 500 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Zuclopenthixol Long-acting IM Injection (Depot) is referenced against Clopixol Depot (EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.